OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Schuster on Long-Term Outcomes of Lenalidomide and Rituximab in MCL

March 8th 2018

Stephen J. Schuster, MD, professor of hematology/oncology at the University of Pennsylvania Abramson Cancer Center, discusses long-term outcomes of lenalidomide (Revlimid) and rituximab (Rituxan) in mantle cell lymphoma (MCL).

Dr. Sandler Discusses Hypofractionation in Prostate Cancer

March 8th 2018

Howard M. Sandler, MD, chair, Department of Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, director, Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses hypofractionation in prostate cancer.

Dr. Venook Discusses Adjuvant Chemotherapy Duration in CRC

March 7th 2018

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses adjuvant chemotherapy duration in colon cancer.

Dr. Kim Discusses Cytoreductive Nephrectomy in Metastatic RCC

March 7th 2018

Hyung L. Kim, MD, Medallion Group Chair in Urology, co-medical director of the Urologic Oncology Center, associate director, Surgical Research in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses cytoreductive nephrectomy in patients with metastatic renal cell carcinoma.

Dr. Blackwell Discusses the HER2CLIMB Study in HER2+ Breast Cancer

March 7th 2018

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the HER2CLIMB study in patients with HER2-positive breast cancer.

Dr. Weber on the FDA Approval for Fixed-Dose of Nivolumab

March 6th 2018

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, 2016 Giant of Cancer Care

Dr. Byrd on Combination Strategies in CLL

March 5th 2018

John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research, professor of medicine, Medicinal Chemistry and Veterinary Biosciences, director, Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, discusses the role of combinations in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Kambhampati Discusses the Current Landscape of MDS

March 5th 2018

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses the current landscape of myelodysplastic syndromes (MDS).

Dr. Postow Discusses Side Effects with Combinations in Melanoma

March 5th 2018

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses side effects with combination therapy in melanoma.

Dr. Balmanoukian on Immunotherapy Advancements in GU Cancers

March 5th 2018

Ani Balmanoukian, MD, director of Thoracic Oncology, associate director of the Phase I Immune-Oncology Program, The Angeles Clinic and Research Institute, discusses immunotherapy advancements in genitourinary cancers.

Dr. Cortes Discusses TKI Cessation in CML

March 3rd 2018

Jorge E. Cortes, MD, professor and deputy chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the success of tyrosine kinase inhibitor (TKI) cessation in patients with chronic myeloid leukemia (CML).

Dr. Graff on the Use of Abiraterone in Metastatic Prostate Cancer

March 3rd 2018

Julie N. Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses treatment for patients with high-risk metastatic disease following the FDA approval of abiraterone acetate (Zytiga).

Dr. Tyson on Rationale For Neoadjuvant Chemotherapy in Bladder Cancer

March 3rd 2018

Mark D. Tyson, MD, urologic oncologist, Mayo Clinic, discusses 2 trials that have shaped physicians’ opinions on the use of neoadjuvant chemotherapy in patients with bladder cancer.

Dr. Coutre Discusses Blinatumomab in MRD-Positive ALL

March 3rd 2018

Steven Coutre, MD, professor of medicine at Stanford University Medical Center, discusses the role of blinatumomab (Blincyto) for patients with minimal residual disease (MRD)-positive acute lymphoblastic leukemia (ALL).

Dr. Bekaii-Saab Discusses PEGPH20 in Pancreatic Adenocarcinoma

March 2nd 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses pegylated recombinant human hyaluronidase (PEGPH20) in pancreatic adenocarcinoma.

Dr. Donnellan Reflects on FDA Approvals in Acute Leukemia

March 2nd 2018

William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, reflects on some of the most pivotal FDA approvals in acute leukemia in the past year.

Dr. Logan Discusses Ibrutinib Plus Venetoclax in CLL

March 2nd 2018

Aaron Logan, MD, PhD, assistant professor of clinical medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in chronic lymphocytic leukemia.

Dr. Singh on Patient Selection for Immunotherapy in Bladder Cancer

March 2nd 2018

Parminder Singh, MD, Hematologist/Oncologist, Mayo Clinic, discusses treatment selection for patients with bladder cancer. At this point, patient selection is based on the approval or labeling indications of the drug, where the patient lies in the spectrum of disease, and whether or not they have any alternative options.

Dr. Ho on How Molecular Subtypes Affect Sequencing

March 2nd 2018

Thai H. Ho, MD, PhD, assistant professor of medicine, Mayo Clinic, discusses common molecular subtype and phenotype alterations in the epigenetic pathway that are used to predict response to treatment.

Dr. Skarbnik on Combination Strategies of Immunotherapy in Hematologic Malignancies

March 2nd 2018

Alan Skarbnik, MD, staff physician, department of Bone Marrow Transplant, Department of Lymphoma, John Theurer Cancer Center, discusses combination strategies with immunotherapy for patients with hematologic malignancies.